Sensyne Health PLC
LSE:SENS
Intrinsic Value
Sensyne Health Plc is a healthcare technology company, which engages in the discovery and development of new medicines. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of SENS.
Sensyne Health PLC's market capitalization is 576.8k GBX.
SENS stock price is 0.35 GBX.
SENS.
SENS. Open DCF Valuation
SENS. Open Relative Valuation
SENS.
SENS's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -121% to -132%, and is approaching profitability.
SENS's Revenue has grown by an exceptional 96% over the past 12 months.
SENS's ROE (Return on Equity) has significantly decreased in the last 3 years from -60% to -109%, and is approaching profitability.
SENS has positive Gross Profit for the last twelve months.
SENS's short-term assets (14m GBP) exceed its short-term liabilties (6m GBP).
SENS has negative Operating Income for the last twelve months.
SENS has negative Net Income for the last twelve months.
SENS's ROE (Return on Equity) for the past 12 months is negative and is equal to -109%.
SENS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -132%.
SENS has negative Free Cash Flow for the last twelve months.
SENS's D/E (Debt to Equity) is very low and is equal to 0.05.
SENS has negative three-year average ROE (Return on Equity): -58%. The company is not efficient at transforming stockholders' equity into net income.
SENS has negative three-year average ROIC (Return on Invested Capital): -107%. The company is not efficient at using invested capital to generate operating income.
SENS's long-term assets (42m GBP) exceed its long-term liabilties (9m GBP).
SENS has negative Net Debt. This means that the company has more cash and short-term investments (8m GBP) than debt (2m GBP).
SENS's Altman Z-Score is very high and is equal to 5.75.
SENS doesn't generate enough operating income (-35m GBP) to safely cover interest payments on its debt (10k GBP).
Fundamental Analysis
Sensyne Health PLC
Balance Sheet Decomposition
Sensyne Health PLC
| Current Assets | 14.4m |
| Cash & Short-Term Investments | 8.1m |
| Receivables | 6.4m |
| Non-Current Assets | 27.7m |
| Long-Term Investments | 2.3m |
| PP&E | 2.2m |
| Intangibles | 23.2m |
| Current Liabilities | 6.4m |
| Other Current Liabilities | 6.4m |
| Non-Current Liabilities | 2.3m |
| Long-Term Debt | 1.6m |
| Other Non-Current Liabilities | 670k |
Earnings Waterfall
Sensyne Health PLC
|
Revenue
|
7.8m
GBP
|
|
Cost of Revenue
|
-2.8m
GBP
|
|
Gross Profit
|
5m
GBP
|
|
Operating Expenses
|
-40.4m
GBP
|
|
Operating Income
|
-35.4m
GBP
|
|
Other Expenses
|
580k
GBP
|
|
Net Income
|
-34.8m
GBP
|
Free Cash Flow Analysis
Sensyne Health PLC
What is Free Cash Flow?
SENS Profitability Score
Profitability Due Diligence
Sensyne Health PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Sensyne Health PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
SENS Solvency Score
Solvency Due Diligence
Sensyne Health PLC's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Sensyne Health PLC's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SENS Price Targets Summary
Sensyne Health PLC
Shareholder Return
SENS Price
Sensyne Health PLC
| Average Annual Return | 4.17% |
| Standard Deviation of Annual Returns | 95.2% |
| Max Drawdown | -100% |
| Market Capitalization | 576.8k GBX |
| Shares Outstanding | 166 460 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Sensyne Health PLC
Country
Industry
Market Cap
Dividend Yield
Description
Sensyne Health Plc is a healthcare technology company, which engages in the discovery and development of new medicines. The firm offers SENSIGHT platform, which provides a research environment for pharmaceutical and life science companies to analyze deidentified and anonymized patient data to support all stages of research and development. The firm applies clinical artificial intelligence (AI) in the healthcare and life science industries. In healthcare, the Company delivers remote patient monitoring and real-time decision-making systems for healthcare organizations and their patients. In life sciences, the Company analyses anonymized data sets to help life sciences companies to develop medicines. The firm's healthcare products include a variety of applications, including decision-making support, remote patient monitoring, diagnostics, prescribed digital therapeutics and the recording and presentation of healthcare data in a clinical setting.
You don't have any saved screeners yet
